Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Inherited Components of Depression Identified and Treated Successfully in a Groundbreaking Clinical Study Published Today in The Journal of Clinical Psychiatry
  • USA - English


News provided by

Mar 30, 2016, 06:55 ET

Share this article

Share toX

Share this article

Share toX

Youtube
Youtube

Plano, Texas (PRWEB) March 30, 2016 -- A new randomized, double-blind, placebo-controlled, 330 patient study published in the prestigious Journal of Clinical Psychiatry has demonstrated that over forty percent of patients with genetic markers associated with major depression may reach complete remission with a vitamin coenzyme based therapy. The patients selected had all tested positive for MTHFR genes associated with depression. Read the full study here.

“We now may have a true shift in thinking, we have the tools to address the underlying genetic cause of depression, rather than simply providing symptomatic relief to our patients.” Andrew Farah, MD

Post this

The corresponding author commented, “For decades we have been prescribing antidepressants that only block the reuptake, or the degradation, of neurotransmitters that are in short supply, but we now have a therapy that is designed to help the brain synthesize more of these transmitters. This study was designed to address the underlying, genetic cause of depression.”

Dr. Farah elaborated, “We have also known that at least 40% of depressed patients suffer from low folate levels, and when we identify these genetic markers of poor folate metabolism and low folate levels in the brain, we also accept that there are likely other B vitamin coenzyme deficiencies present as well. Simply flooding the system with folate was of little help, because that ignored the very likely possibility of the various other vitamin deficiencies.”

In the modern world, vitamin intake is not the issue, Dr. Farah elaborated, but rather, vitamin metabolism. Most patients and many doctors do not understand that it is the metabolized vitamins that act as coenzymes in the synthesis of neurotransmitters, and there can exist any array of genetic differences that can result in poor vitamin metabolism, a short supply of coenzymes, and thus, a less than optimal supply of serotonin, norepinephrine, and dopamine in these genetically vulnerable individuals.

The Principle Investigator was Dr. Arnold Mech of Plano, Texas. He specifically designed the study to utilize Enlyte, a prescription gel cap containing all the metabolized B vitamins and micronutrients necessary for neurotransmitter synthesis. “Enlyte” is marketed by Jaymac Pharmaceuticals LLC, and is described as an orally-administered prescription folate containing product for the clinical dietary management of depression related to suboptimal folate levels associated with metabolic imbalances in transformylation and/or methylation biochemistry such as MTHFR Polymorphism.

Dr. Mech’s clinics examined 330 patients, half received Enlyte, half received placebo. There was an average drop of 12 points on the Montgomery Asberg Depression Rating Scale, and Dr. Mech believes his results also helped support Dr. Farah’s “Homocysteine Theory of Depression.”

“Homocysteine is an amino acid that is toxic to vessels, to DNA, and to neurons in various ways. When we break down homocysteine, we do four things: We first eliminate its toxic burden in the brain; secondly, we make antioxidants to further protect the brain; third, we create methyl donors for DNA and other compounds, but relevant to Dr. Mech’s study, homocysteine metabolism is critical to the synthesis and methylation of neurotransmitters. Dr. Mech has demonstrated that a majority of depressed individuals responding to Enlyte experienced a significant drop in homocysteine compared to placebo, that corresponded to their clinical response, again, supporting the homocysteine theory of depression”

This study is particularly timely, as the latest edition of The American Psychiatric Association Task Force guidelines for Complementary and Alternative Medicine in Major Depressive Disorder advocates folate/methylfolate and omega-3 fatty acids as augmentation strategies for MDD as routine treatment planning. “Folate may play a role in the relief of MDD as a low risk addition to standard treatments with protective effects against cardiovascular disease in individuals with high levels of homocysteine and the risk of birth defects in pregnant women.” The efficacy of folate monotherapy has yet to be extensively and adequately tested. This study will add to the body of knowledge concerning this issue particularly in the MTHFR polymorphic patient.

Further, no one in the study experienced manic symptoms, and no one experienced an increase in suicidal thinking, and all side effects were on par with placebo rates. Enlyte is also safe in pregnancy. “With the new data linking exposure to antidepressants late in pregnancy with an increased risk of autism, expectant mothers who need antidepressants will welcome this option,” stated Dr. Farah.    

Dr. Farah elaborated that this data, if replicated, will represent a true paradigm shift in how we address depression, “we now may have a true shift in thinking, we have the tools to address the underlying genetic cause of depression, rather than simply providing symptomatic relief to our patients.”

Andrew Farah, MD, Chief of Psychiatry, HPRHS/UNC Healthcare, +1 850-602-1617, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.